Gosset -- Biotech intelligence platform

Phase 1a/1b

Phase 2a/2b

Phase 3

Sort by
Drug ENTR-601-44	Company Entrada Therapeutics	Symbol TRDA	Conditions Duchenne Muscular Dystrophy	Phase Phase 1	Date 2024-10-08	Description Presentation of positive preliminary data from Phase 1 ENTR-601-44-101 trial	Uncertainty
Drug obefazimod	Company Abivax	Symbol ABVX	Conditions ulcerative colitis	Phase N/A	Date 2024-10-12	Description Abivax will participate and present at United European Gastroenterology Week 2024.	Uncertainty
Drug tamibarotene	Company Syros Pharmaceuticals	Symbol SYRS	Conditions higher-risk myelodysplastic syndrome	Phase Phase 3	Date 2024-10-15	Description Pivotal CR data from the SELECT-MDS-1 Phase 3 trial expected by mid-4Q 2024.	Uncertainty
Drug ABP-450	Company AEON Biopharma	Symbol AEON	Conditions episodic migraine	Phase Phase 2	Date 2024-10-19	Description Management to host a conference call to discuss topline results from Phase 2 trial of ABP-450 for episodic migraine.	Uncertainty
Drug sebetralstat	Company KalVista Pharmaceuticals	Symbol KALV	Conditions hereditary angioedema (HAE)	Phase Phase 3	Date 2024-10-24	Description KalVista intends to present additional data from the KONFIDENT and KONFIDENT-S trials.	Uncertainty
Drug obefazimod	Company Abivax	Symbol ABVX	Conditions ulcerative colitis	Phase N/A	Date 2024-10-25	Description Abivax will participate and present at the American College of Gastroenterology Scientific Meeting 2024.	Uncertainty
Drug fosgonimeton	Company Athira Pharma	Symbol ATHA	Conditions Alzheimer's disease	Phase	Date 2024-10-29	Description Athira Pharma to present fuller data set from the LIFT-AD trial in an oral presentation at CTAD.	Uncertainty
Drug ZTALMY (ganaxolone) oral suspension CV	Company Marinus Pharmaceuticals	Symbol MRNS	Conditions tuberous sclerosis complex	Phase Phase 3	Date 2024-10-31	Description Topline results from the Phase 3 TrustTSC trial for ZTALMY (ganaxolone) oral suspension CV in tuberous sclerosis complex.	Uncertainty
Drug Mounjaro , tirzepatide	Company Eli Lilly	Symbol LLY	Conditions obesity, overweight	Phase	Date 2024-11	Description Results from head-to-head comparison of tirzepatide and semaglutide in overweight or obese adults without type 2 diabetes.	Uncertainty
Drug tamibarotene	Company Syros Pharmaceuticals	Symbol SYRS	Conditions Higher-Risk Myelodysplastic Syndrome	Phase Phase 3	Date 2024-11-01	Description Pivotal CR data from the SELECT-MDS-1 trial.	Uncertainty
Drug Blenrep	Company GSK	Symbol GSK	Conditions multiple myeloma	Phase Phase 3	Date 2024-11-01	Description Full data from the DREAMM-7 trial will be presented at an upcoming scientific congress.	Uncertainty
Drug Fabhalta	Company Novartis	Symbol NVS	Conditions C3 glomerulopathy (C3G)	Phase Phase 3	Date 2024-11-01	Description Presentation of additional 6-month open-label period data for Fabhalta in C3G.	Uncertainty
Drug COMP360	Company COMPASS Pathways	Symbol CMPS	Conditions treatment-resistant depression	Phase Phase 3	Date 2024-11-02	Description Initial top-line data for COMP005 expected in less than a year	Uncertainty
Drug isaralgagene civaparvovec , giroctocogene fitelparvovec	Company Sangamo Therapeutics	Symbol SGMO	Conditions Fabry Disease, Hemophilia A	Phase N/A	Date 2024-11-02	Description The Sangamo management team will discuss these results on a conference call.	Uncertainty
Drug DFD-29	Company Journey Medical	Symbol DERM	Conditions rosacea	Phase N/A	Date 2024-11-04	Description FDA decision on the New Drug Application for DFD-29.	Uncertainty
Drug TH104	Company Tharimmune	Symbol THAR	Conditions chronic pruritis, primary biliary cholangitis (PBC)	Phase Phase 2	Date 2024-11-06	Description Tharimmune expects to complete a phase 1 pharmacokinetic trial and a phase 2 proof-of-concept efficacy study in PBC patients suffering from chronic pruritis over approximately 12 months after aligning with FDA on trial design.	Uncertainty
Drug REACT	Company ProKidney	Symbol PROK	Conditions diabetic CKD	Phase Phase 2	Date 2024-11-14	Description ProKidney will host a conference call and webcast to discuss updated interim data from its RMCL-002 Phase 2 study.	Uncertainty
Drug REACT®	Company ProKidney	Symbol PROK	Conditions diabetic CKD	Phase Phase 2	Date 2024-11-14	Description ProKidney will host a conference call to discuss updated interim data from its RMCL-002 Phase 2 study.	Uncertainty
Drug RP-1664 , RP-3467	Company Repare Therapeutics	Symbol RPTX	Conditions TRIM37-high tumors, HRD tumors	Phase Phase 1	Date 2024-11-15	Description Repare Therapeutics plans to advance RP-1664 and RP-3467 into Phase 1 clinical trials in 2024.	Uncertainty
Drug fosgonimeton	Company Athira Pharma	Symbol ATHA	Conditions Alzheimer’s disease	Phase N/A	Date 2024-11-15	Description Presentation of new preclinical data supporting the potential therapeutic benefit of fosgonimeton for the treatment of Alzheimer’s disease.	Uncertainty
Drug tamibarotene	Company Syros Pharmaceuticals	Symbol SYRS	Conditions higher-risk myelodysplastic syndrome	Phase Phase 3	Date 2024-11-15	Description Syros expects to report pivotal complete response data for tamibarotene in SELECT-MDS-1 trial.	Uncertainty
Drug nomlabofusp	Company Larimar Therapeutics	Symbol LRMR	Conditions Friedreich's ataxia	Phase Phase 2	Date 2024-12-01	Description Interim data report from the open-label extension (OLE) trial.	Uncertainty
Drug briquilimab	Company Jasper Therapeutics	Symbol JSPR	Conditions chronic inducible urticaria	Phase	Date 2024-12-01	Description Initial data readout from Phase 1b/2a SPOTLIGHT study in chronic inducible urticaria	Uncertainty
Drug dalzanemdor	Company Sage Therapeutics	Symbol SAGE	Conditions Huntington’s disease	Phase Phase 2	Date 2024-12-01	Description Topline data from the DIMENSION study in people with Huntington’s disease cognitive impairment.	Uncertainty
Drug Casgevy	Company CRISPR Therapeutics	Symbol CRSP	Conditions Severe sickle cell disease	Phase N/A	Date 2024-12-08	Description US FDA decision on Casgevy for severe sickle cell disease	Uncertainty
Drug AG-946	Company Agios Pharmaceuticals	Symbol AGIO	Conditions anemia, lower-risk myelodysplastic syndromes (LR-MDS)	Phase Phase 2a	Date 2024-12-09	Description Agios and its collaborators will present preclinical data supporting its MDS clinical development program.	Uncertainty
Drug INB-100	Company IN8bio	Symbol INAB	Conditions hematologic malignancies, AML	Phase Phase 1	Date 2024-12-11	Description Updated data from the INB-100 Phase 1 trial will be presented at medical meetings in 2024.	Uncertainty
Drug CFT7455	Company C4 Therapeutics	Symbol CCCC	Conditions multiple myeloma	Phase Phase 1	Date 2024-12-12	Description C4 Therapeutics will host an investor webcast to discuss the CFT7455 Phase 1 clinical data in relapsed/refractory multiple myeloma.	Uncertainty
Drug tamibarotene	Company Syros Pharmaceuticals	Symbol SYRS	Conditions acute myeloid leukemia	Phase Phase 2	Date 2024-12-15	Description Additional data from the SELECT-AML-1 Phase 2 trial expected in 2024.	Uncertainty
Drug ADX-629	Company Aldeyra Therapeutics	Symbol ALDX	Conditions atopic dermatitis	Phase Phase 2	Date 2024-12-19	Description Aldeyra will host a conference call to discuss the top-line results of the Phase 2 clinical trial of ADX-629 in atopic dermatitis.	Uncertainty
Drug olezarsen	Company Ionis Pharmaceuticals	Symbol IONS	Conditions familial chylomicronemia syndrome	Phase N/A	Date 2024-12-19	Description FDA decision on olezarsen NDA for treatment of familial chylomicronemia syndrome	Uncertainty
Drug Zynquista , sotagliflozin	Company Lexicon Pharmaceuticals	Symbol LXRX	Conditions type 1 diabetes, chronic kidney disease	Phase N/A	Date 2024-12-20	Description FDA target action date for Zynquista (sotagliflozin) marketing application review	Uncertainty
Drug crinecerfont	Company Neurocrine Biosciences	Symbol NBIX	Conditions congenital adrenal hyperplasia (CAH)	Phase N/A	Date 2024-12-29	Description FDA decision on crinecerfont capsule formulation for CAH treatment	Uncertainty
Drug IMNN-101	Company IMUNON	Symbol IMNN	Conditions Covid-19	Phase Phase 1	Date 2024-12-31	Description Topline data from the Phase 1 study of IMNN-101 in Covid-19 expected by year-end.	Uncertainty
Drug NKX019	Company Nkarta Inc.	Symbol NKTX	Conditions AID	Phase Phase 1	Date 2024-12-31	Description Nkarta will announce clinical updates from its NKX019 program in autoimmune diseases in 2024.	Uncertainty
Drug EB613	Company Entera Bio	Symbol ENTX	Conditions Osteoporosis	Phase Phase 3	Date 2024-12-31	Description Entera Bio looks forward to initiating its pivotal phase 3 study for EB613 once the final qualification of the SABRE endpoint is announced by FDA.	Uncertainty
Drug revumenib	Company Syndax Pharmaceuticals	Symbol SNDX	Conditions KMT2A-rearranged acute leukemias, NPM1-mutant AML	Phase Phase 2	Date 2024-12-31	Description Topline data from the AUGMENT-101 mNPM1 patient cohort expected in Q4 2024.	Uncertainty
Drug BDTX-4933	Company Black Diamond Therapeutics	Symbol BDTX	Conditions non-G12C KRAS mutated NSCLC	Phase Phase 1	Date 2024-12-31	Description Initial Phase 1 data for BDTX-4933 in non-G12C KRAS mutated NSCLC.	Uncertainty
Drug Niyad	Company Talphera	Symbol TLPH	Conditions extracorporeal circuit	Phase N/A	Date 2024-12-31	Description Expected pre-market approval (PMA) application submission	Uncertainty
Drug briquilimab	Company Jasper Therapeutics	Symbol JSPR	Conditions chronic inducible urticaria	Phase	Date 2024-12-31	Description Initial results from the SPOTLIGHT study in chronic inducible urticaria	Uncertainty
Drug eblasakimab	Company ASLAN Pharmaceuticals	Symbol ASLN	Conditions atopic dermatitis	Phase Phase 2	Date 2024-12-31	Description Topline unblinded data from the full dataset of the TREK-DX study is expected.	Uncertainty
Drug setanaxib	Company Calliditas Therapeutics	Symbol CALT	Conditions primary IgA nephropathy (IgAN)	Phase Phase 2	Date 2024-12-31	Description Calliditas is targeting top line readout of several Phase 2 clinical trials with setanaxib in 2024.	Uncertainty
Drug Sevasemten	Company Edgewise Therapeutics	Symbol EWTX	Conditions Duchenne Muscular Dystrophy	Phase Phase 2	Date 2024-12-31	Description Data readout from the LYNX Phase 2 trial in boys with Duchenne Muscular Dystrophy.	Uncertainty
Drug GRI-0621	Company GRI Bio	Symbol GRI	Conditions idiopathic pulmonary fibrosis	Phase Phase 2a	Date 2024-12-31	Description Topline results from the Phase 2a study for GRI-0621 in idiopathic pulmonary fibrosis.	Uncertainty
Drug ABI-4334	Company Assembly Biosciences	Symbol ASMB	Conditions Chronic Hepatitis B Virus Infection	Phase Phase 1b	Date 2024-12-31	Description Interim results from the Phase 1b study of ABI-4334 in chronic hepatitis B virus infection.	Uncertainty
Drug Anaphylm	Company Aquestive Therapeutics	Symbol AQST	Conditions severe life-threatening allergic reactions, anaphylaxis	Phase N/A	Date 2024-12-31	Description Conducting a pediatric study for Anaphylm, if agreed upon with the FDA.	Uncertainty
Drug ALG-000184	Company Aligos Therapeutics	Symbol ALGS	Conditions chronic hepatitis B (CHB)	Phase Phase 2	Date 2024-12-31	Description Completion of Phase 2 enabling activities for ALG-000184	Uncertainty
Drug GSBR-1290	Company Structure Therapeutics	Symbol GPCR	Conditions obesity, overweight	Phase Phase 2b	Date 2024-12-31	Description Structure Therapeutics aims to initiate a 36-week Phase IIb global obesity study involving 300 participants.	Uncertainty
Drug tamibarotene	Company Syros Pharmaceuticals	Symbol SYRS	Conditions higher-risk myelodysplastic syndrome (MDS)	Phase Phase 3	Date 2024-12-31	Description Pivotal complete response data from SELECT-MDS-1 is expected by the middle of the fourth quarter of 2024.	Uncertainty
Drug PGN-EDODM1	Company PepGen Inc	Symbol PEPG	Conditions Myotonic Dystrophy 1 (DM1)	Phase Phase 1	Date 2024-12-31	Description Preliminary data from at least the 5 mg/kg dose cohort.	Uncertainty

Sort by
Title WuXi debates sale of pharma operations as BIOSECURE Act advances	Categories	Conditions	Drugs	Companies	Date 2024-10-04 22:46:55
Title New garment may protect techs from radiation-associated cancers	Categories US results	Conditions breast cancer	Drugs	Companies John Peter Smith Hospital Burlington Medical Supplies	Date 2024-10-04 18:38:43
Title MITA urges 'one stability, one facility' with PET drug inspections	Categories US	Conditions	Drugs PET	Companies Medical Imaging and Technology Alliance Coalition of PET Drug Manufacturers U.S. Food and Drug Administration National Electrical Manufacturers Association	Date 2024-10-04 17:35:29
Title Ottobock and Kennesaw State University Collaborate for Mobility Clinic, Empowering and Building Community Thro	Categories partnership US	Conditions	Drugs	Companies Ottobock Kennesaw State University	Date 2024-10-04 17:05:04
Title FDA lifts clinical hold on Avidity’s lead antibody conjugate therapy trial	Categories	Conditions	Drugs	Companies	Date 2024-10-04 14:38:41
Title Aero Pump and Resyca Partner to Launch Ultra Soft Nasal Pump Spray, Targeting Precise Nasal Drug Delivery Appl	Categories partnership US	Conditions	Drugs	Companies Aero Pump Resyca Bespak Medspray Ursatec	Date 2024-10-04 14:00:08
Title Justera Health Announces Debt Settlement Transaction	Categories financial statement other	Conditions	Drugs	Companies Justera Health Ltd.	Date 2024-10-04 13:40:04
Title Aero Pump and Resyca Partner to Launch Ultra Soft Nasal Pump Spray, Targeting Precise Nasal Drug Delivery Appl	Categories partnership US	Conditions	Drugs	Companies Aero Pump Resyca Bespak Medspray Ursatec	Date 2024-10-04 13:05:06
Title NHS proposes phased launch for Eli Lilly’s Mounjaro	Categories	Conditions	Drugs	Companies	Date 2024-10-04 12:44:07
Title Better Together: Nasser Orthodontics Will Merge With Cosse & Silmon Orthodontics on October 1, 2024	Categories M&A partnership	Conditions	Drugs	Companies Nasser Orthodontics Cosse & Silmon Orthodontics	Date 2024-10-04 12:05:15